A study in healthy subjects to assess bioavailability (proportion of a drug which enters the circulation to have an active effect) of acalabrutinib tablet and protonpump inhibitor effect (members of a class of medications that inhibits in gastric acid production) for Rabeprazole

Trial Identifier: D8223C00005
Sponsor: AstraZeneca
Collaborator:
Parexel International
NCTID:: NCT04564040
Start Date: October 2020
Primary Completion Date: December 2020
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English version
German Translation

Trial Locations

Country Location
Germany Berlin, Germany, 14050